SENTARA COMMUNITY PLAN
(MEDICAID)

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; **fax to 1-800-750-9692.** No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If information provided is not complete, correct, or legible, authorization may be delayed.**

Drug Requested: Ztalmy® (ganaxolone)

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name: _____

Member Sentara #: _____ **Date of Birth:** _____

Prescriber Name: _____

Prescriber Signature: _____ **Date:** _____

Office Contact Name: _____

Phone Number: _____ **Fax Number:** _____

DEA OR NPI #: _____

DRUG INFORMATION: Authorization may be delayed if incomplete.

Drug Form/Strength: _____

Dosing Schedule: _____ **Length of Therapy:** _____

Diagnosis: _____ **ICD Code:** _____

Weight: _____ **Date:** _____

Members weighing 28 kg or less		**Members weighing more than 28 kg**	
Days of Therapy	**Maximum Total Daily Dose**	**Days of Therapy**	**Maximum Total Daily Dose**
1 to 7	6 mg/kg 3 times daily **18 mg/kg/day**	1 to 7	150 mg 3 times daily **450 mg**
8 to 14	11 mg/kg 3 times daily **33 mg/kg/day**	8 to 14	300 mg 3 times daily **900 mg**
15 to 21	16 mg/kg 3 times daily **48 mg/kg/day**	15 to 21	450 mg 3 times daily **1350 mg**
22 and ongoing	21 mg/kg 3 times daily **63 mg/kg/day**	22 and ongoing	600 mg 3 times daily **1800 mg**

Quantity Limit: 10 bottles per 30 days

(Continued on next page)

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

Initial Authorization: 12 months

- ❑ Medication must be prescribed by or in consultation with a neurologist geneticist, or physician who is specialized in the treatment of epileptic disorders
- ❑ Member must be 2 years of age or older
- ❑ Member has a diagnosis of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD)
- ❑ Documentation that seizures have been inadequately controlled by a trial of at least 2 antiepileptic drugs (e.g., clobazam, valproate, lamotrigine, levetiracetam, topiramate, felbamate, vigabatrin) or member has labeled contraindications to other antiepileptic drugs

Reauthorization: 12 months. All criteria that apply must be checked for approval. To support each line checked, all documentation (lab results, diagnostics, and/or chart notes) must be provided or request may be denied.

- ❑ Documentation of positive clinical response as demonstrated by low disease activity and/or improvements in the condition's signs and symptoms (e.g., reduced seizure activity, frequency, and/or duration)

*****Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.*****

****Previous therapies will be verified through pharmacy paid claims or submitted chart notes.****

Approved by Pharmacy and Therapeutics Committee: 9/15/2022 **REVISED/UPDATED: 9/21/2023**